Swiss National Bank grew its stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 9.3% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 61,000 shares of the medical instruments supplier’s stock after acquiring an additional 5,200 shares during the period. Swiss National Bank owned 0.17% of AngioDynamics worth $989,000 as of its most recent SEC filing.
Several other institutional investors also recently bought and sold shares of ANGO. Dimensional Fund Advisors LP boosted its holdings in AngioDynamics by 0.5% in the first quarter. Dimensional Fund Advisors LP now owns 3,128,777 shares of the medical instruments supplier’s stock worth $54,285,000 after purchasing an additional 14,823 shares in the last quarter. Vanguard Group Inc. boosted its holdings in AngioDynamics by 7.4% in the first quarter. Vanguard Group Inc. now owns 1,694,290 shares of the medical instruments supplier’s stock worth $29,396,000 after purchasing an additional 116,814 shares in the last quarter. Royce & Associates LP boosted its holdings in AngioDynamics by 15.8% in the second quarter. Royce & Associates LP now owns 938,148 shares of the medical instruments supplier’s stock worth $15,207,000 after purchasing an additional 127,836 shares in the last quarter. Peregrine Capital Management LLC bought a new stake in AngioDynamics in the second quarter worth $12,133,000. Finally, Fenimore Asset Management Inc. boosted its holdings in AngioDynamics by 9.1% in the second quarter. Fenimore Asset Management Inc. now owns 579,225 shares of the medical instruments supplier’s stock worth $9,389,000 after purchasing an additional 48,150 shares in the last quarter. Institutional investors and hedge funds own 95.42% of the company’s stock.
WARNING: This report was first published by Transcript Daily and is owned by of Transcript Daily. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://transcriptdaily.com/2017/10/18/angiodynamics-inc-ango-shares-bought-by-swiss-national-bank.html.
In related news, CEO James C. Clemmer bought 20,000 shares of AngioDynamics stock in a transaction that occurred on Thursday, July 20th. The stock was acquired at an average price of $15.64 per share, with a total value of $312,800.00. Following the acquisition, the chief executive officer now owns 86,683 shares of the company’s stock, valued at approximately $1,355,722.12. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO James C. Clemmer bought 5,000 shares of AngioDynamics stock in a transaction that occurred on Friday, July 21st. The shares were bought at an average cost of $15.79 per share, with a total value of $78,950.00. Following the acquisition, the chief executive officer now directly owns 86,683 shares in the company, valued at approximately $1,368,724.57. The disclosure for this purchase can be found here. Insiders have purchased a total of 25,316 shares of company stock valued at $396,806 in the last ninety days. 1.80% of the stock is currently owned by insiders.
AngioDynamics, Inc. (ANGO) opened at 17.22 on Wednesday. AngioDynamics, Inc. has a 12 month low of $14.80 and a 12 month high of $18.85. The stock’s 50 day moving average is $17.36 and its 200-day moving average is $16.36. The firm has a market cap of $632.23 million, a price-to-earnings ratio of 173.94 and a beta of 1.12.
AngioDynamics (NASDAQ:ANGO) last announced its earnings results on Thursday, September 28th. The medical instruments supplier reported $0.12 EPS for the quarter, missing the consensus estimate of $0.16 by ($0.04). The company had revenue of $85.40 million for the quarter, compared to the consensus estimate of $86.12 million. AngioDynamics had a return on equity of 4.83% and a net margin of 1.64%. The business’s quarterly revenue was down 3.1% on a year-over-year basis. During the same period in the previous year, the firm posted $0.17 EPS. On average, analysts anticipate that AngioDynamics, Inc. will post $0.66 earnings per share for the current fiscal year.
A number of brokerages recently issued reports on ANGO. Cantor Fitzgerald upped their price objective on shares of AngioDynamics from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Tuesday, July 4th. KeyCorp restated a “hold” rating on shares of AngioDynamics in a report on Friday, September 29th. Barclays PLC decreased their price target on shares of AngioDynamics from $17.00 to $16.00 and set an “equal weight” rating for the company in a report on Wednesday, July 19th. Canaccord Genuity restated a “hold” rating and set a $17.00 price target on shares of AngioDynamics in a report on Tuesday, July 18th. Finally, Zacks Investment Research upgraded shares of AngioDynamics from a “sell” rating to a “hold” rating in a report on Monday, August 14th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $18.60.
AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.
Receive News & Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.